Karolinska Development AB (publ) (KDEV.ST)
SEK 1.07
(3.5%)
SEK 1.07
(3.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.5 Million SEK | 97.81% |
| 2022 | -87.42 Million SEK | -154.4% |
| 2021 | 160.7 Million SEK | 179.39% |
| 2020 | -202.42 Million SEK | -158.18% |
| 2019 | 347.94 Million SEK | 369.92% |
| 2018 | 74.04 Million SEK | -66.42% |
| 2017 | 220.51 Million SEK | 226.69% |
| 2016 | -174.04 Million SEK | 82.94% |
| 2015 | -1.02 Billion SEK | -174.11% |
| 2014 | -372.21 Million SEK | -357.99% |
| 2013 | 144.27 Million SEK | 156.84% |
| 2012 | -253.81 Million SEK | 36.65% |
| 2011 | -400.67 Million SEK | -16.05% |
| 2010 | -345.26 Million SEK | -2464.92% |
| 2009 | -13.46 Million SEK | -90.83% |
| 2008 | -7.05 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.52 Million SEK | 64.88% |
| 2024 Q2 | -17.51 Million SEK | -1052.24% |
| 2023 FY | -1.91 Million SEK | 97.81% |
| 2023 Q4 | -4.32 Million SEK | -145.9% |
| 2023 Q3 | 9.43 Million SEK | -55.7% |
| 2023 Q1 | 15.18 Million SEK | 72.26% |
| 2023 Q2 | 21.28 Million SEK | 40.17% |
| 2022 Q4 | 8.81 Million SEK | -75.84% |
| 2022 Q2 | 5 Million SEK | -21.32% |
| 2022 Q1 | 6.36 Million SEK | 136.38% |
| 2022 FY | -87.42 Million SEK | -154.4% |
| 2022 Q3 | 36.49 Million SEK | 628.65% |
| 2021 Q3 | -5.32 Million SEK | -102.57% |
| 2021 Q2 | 207.41 Million SEK | 967.92% |
| 2021 Q4 | -17.49 Million SEK | -228.83% |
| 2021 FY | 160.7 Million SEK | 179.39% |
| 2021 Q1 | -23.89 Million SEK | -127.4% |
| 2020 Q1 | -125.5 Million SEK | -137.85% |
| 2020 FY | -202.42 Million SEK | -158.18% |
| 2020 Q3 | -168.01 Million SEK | -4432.54% |
| 2020 Q4 | 87.21 Million SEK | 151.91% |
| 2020 Q2 | 3.87 Million SEK | 103.09% |
| 2019 Q2 | 21.39 Million SEK | 631.24% |
| 2019 Q4 | 331.53 Million SEK | 34599.06% |
| 2019 FY | 347.94 Million SEK | 369.92% |
| 2019 Q3 | -961 Thousand SEK | -104.49% |
| 2019 Q1 | -4.02 Million SEK | -114.49% |
| 2018 Q3 | 13.95 Million SEK | -66.55% |
| 2018 Q1 | -9.4 Million SEK | -122.7% |
| 2018 FY | 74.04 Million SEK | -66.42% |
| 2018 Q4 | 27.79 Million SEK | 99.2% |
| 2018 Q2 | 41.7 Million SEK | 543.59% |
| 2017 Q1 | -13.28 Million SEK | -10.09% |
| 2017 Q4 | 41.42 Million SEK | -79.67% |
| 2017 Q2 | -11.41 Million SEK | 14.1% |
| 2017 FY | 220.51 Million SEK | 226.69% |
| 2017 Q3 | 203.78 Million SEK | 1885.58% |
| 2016 Q1 | -90.06 Million SEK | 19.14% |
| 2016 FY | -174.04 Million SEK | 82.94% |
| 2016 Q3 | -6.96 Million SEK | 89.28% |
| 2016 Q4 | -12.06 Million SEK | -73.29% |
| 2016 Q2 | -64.94 Million SEK | 27.89% |
| 2015 Q3 | -20.89 Million SEK | 96.77% |
| 2015 FY | -1.02 Billion SEK | -174.11% |
| 2015 Q1 | -265.95 Million SEK | -559.69% |
| 2015 Q2 | -646.2 Million SEK | -142.98% |
| 2015 Q4 | -111.39 Million SEK | -433.14% |
| 2014 Q2 | -188.85 Million SEK | -914.08% |
| 2014 FY | -372.21 Million SEK | -357.99% |
| 2014 Q4 | -40.31 Million SEK | 67.6% |
| 2014 Q3 | -124.42 Million SEK | 34.11% |
| 2014 Q1 | -18.62 Million SEK | 87.79% |
| 2013 Q4 | -152.49 Million SEK | -66.03% |
| 2013 Q3 | -91.85 Million SEK | -8192.51% |
| 2013 Q2 | 1.13 Million SEK | -99.71% |
| 2013 FY | 144.27 Million SEK | 156.84% |
| 2013 Q1 | 387.48 Million SEK | 677.05% |
| 2012 Q2 | -107.34 Million SEK | -12.78% |
| 2012 Q1 | -95.17 Million SEK | 67.3% |
| 2012 Q4 | 49.86 Million SEK | 149.3% |
| 2012 Q3 | -101.15 Million SEK | 5.77% |
| 2012 FY | -253.81 Million SEK | 36.65% |
| 2011 Q1 | -41.62 Million SEK | 0.0% |
| 2011 Q4 | -291.05 Million SEK | -103.57% |
| 2011 FY | -400.67 Million SEK | -16.05% |
| 2011 Q2 | -90.01 Million SEK | -116.28% |
| 2011 Q3 | -142.97 Million SEK | -58.84% |
| 2010 FY | -345.26 Million SEK | -2464.92% |
| 2010 Q3 | - SEK | 0.0% |
| 2009 FY | -13.46 Million SEK | -90.83% |
| 2008 FY | -7.05 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 98.592% |
| Ziccum AB (publ) | -21.56 Million SEK | 83.743% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 78.629% |
| BioArctic AB (publ) | 252.64 Million SEK | 101.387% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -314.793% |
| Mendus AB (publ) | -100.65 Million SEK | 96.518% |
| Genovis AB (publ.) | 54.22 Million SEK | 106.464% |
| Intervacc AB (publ) | -93.57 Million SEK | 96.255% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 77.405% |
| Active Biotech AB (publ) | -46.48 Million SEK | 92.46% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 119.462% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 93.675% |
| Aptahem AB (publ) | -10.1 Million SEK | 65.313% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 98.91% |
| Kancera AB (publ) | -65.04 Million SEK | 94.611% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 97.396% |
| Fluicell AB (publ) | -26.87 Million SEK | 86.96% |
| Saniona AB (publ) | -81.06 Million SEK | 95.676% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | 71.668% |
| Biovica International AB (publ) | -126.07 Million SEK | 97.22% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 91.754% |
| AcouSort AB (publ) | -17.48 Million SEK | 79.957% |
| Xintela AB (publ) | -57.23 Million SEK | 93.876% |
| Abliva AB (publ) | -96.54 Million SEK | 96.37% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 98.921% |
| OncoZenge AB (publ) | -15.9 Million SEK | 77.959% |
| Amniotics AB (publ) | -29.07 Million SEK | 87.944% |
| 2cureX AB (publ) | -36.36 Million SEK | 90.361% |
| CombiGene AB (publ) | -36.3 Million SEK | 90.346% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | 76.059% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 99.088% |
| Camurus AB (publ) | 532.35 Million SEK | 100.658% |
| Corline Biomedical AB | -1.78 Million SEK | -96.029% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 98.061% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 91.591% |
| I-Tech AB | 24.43 Million SEK | 114.344% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 99.555% |
| Cyxone AB (publ) | -21.66 Million SEK | 83.819% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 96.692% |
| Biosergen AB | -27.26 Million SEK | 87.145% |
| Cantargia AB (publ) | -290.01 Million SEK | 98.791% |
| NextCell Pharma AB | -43.17 Million SEK | 91.881% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 98.061% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 79.498% |
| Nanologica AB (publ) | -69.96 Million SEK | 94.99% |
| SynAct Pharma AB | -224.49 Million SEK | 98.439% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 92.066% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 85.368% |
| LIDDS AB (publ) | -40.67 Million SEK | 91.383% |
| Lipum AB (publ) | -37.25 Million SEK | 90.592% |
| BioInvent International AB (publ) | -369.94 Million SEK | 99.053% |
| Alzinova AB (publ) | -16.52 Million SEK | 78.786% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 98.617% |
| Pila Pharma AB (publ) | -6.39 Million SEK | 45.177% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 96.954% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 82.596% |
| Simris Alg AB (publ) | -36.63 Million SEK | 90.433% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 97.609% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 98.871% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 96.84% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | 69.696% |